This inventor holds 1 USPTO granted patent and 5 published patent applications. Top assignee: Abbvie Inc.. Active years: 2022.
Company Filing History:
Years Active: 2022
Title: Michael Simon: Innovator in Pharmaceutical Compositions
Introduction
Michael Simon is a notable inventor based in Landau, Germany. He has made significant contributions to the field of pharmaceuticals, particularly in the treatment of Hepatitis C Virus (HCV). His innovative work has led to the development of a unique solid pharmaceutical composition that showcases his expertise and dedication to improving healthcare.
Latest Patents
Michael Simon holds 1 patent for his invention titled "Solid pharmaceutical compositions for treating HCV." This patent features solid pharmaceutical compositions that comprise Compound 1 and Compound 2. In one embodiment, the solid pharmaceutical composition includes a first layer comprising 100 mg of Compound 1, along with a pharmaceutically acceptable hydrophilic polymer and a pharmaceutically acceptable surfactant, all formulated in amorphous solid dispersion. Additionally, a second layer comprises 40 mg of Compound 2, also formulated with a hydrophilic polymer and surfactant in amorphous solid dispersion.
Career Highlights
Michael Simon is associated with AbbVie Inc., a leading global biopharmaceutical company. His work at AbbVie has allowed him to focus on innovative solutions for complex health issues, particularly in the realm of viral infections. His contributions have been instrumental in advancing pharmaceutical research and development.
Collaborations
Throughout his career, Michael has collaborated with talented professionals, including Thomas Mueller and Constanze Obermiller. These collaborations have fostered a creative environment that encourages innovation and the sharing of ideas.
Conclusion
Michael Simon's work in developing solid pharmaceutical compositions for treating HCV exemplifies his commitment to advancing medical science. His innovative approach and collaboration with esteemed colleagues continue to make a significant impact in the pharmaceutical industry.